4577 — Daito Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00- ¥33bn
- ¥39bn
- ¥47bn
- 57
- 78
- 62
- 78
Annual cashflow statement for Daito Pharmaceutical Co, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 5,595 | 5,874 | 6,720 | 5,076 | 4,218 |
| Depreciation | |||||
| Non-Cash Items | -225 | 105 | -174 | 30 | -418 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4,015 | -3,951 | -5,488 | -4,820 | -2,276 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 4,306 | 5,183 | 4,371 | 4,156 | 5,183 |
| Capital Expenditures | -2,773 | -6,350 | -4,733 | -5,556 | -6,276 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 91.8 | 25.3 | 333 | -10 | 346 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,681 | -6,324 | -4,400 | -5,566 | -5,930 |
| Financing Cash Flow Items | 7.83 | -0.002 | 80 | -2 | -1 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -350 | 1,425 | 989 | 616 | -183 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,265 | 289 | 1,008 | -774 | -879 |